

LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K

February 05, 2002

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange  
Act of 1934

FEBRUARY 5, 2002

-----

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

-----

(Address of principal executive offices)

336-229-1127

-----

(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure.

Laboratory Corporation of America -Registered Trademark-  
Holdings (LabCorp -Registered Trademark-) (NYSE:LH) announced  
that Thomas P. Mac Mahon, chairman and chief executive  
officer, is scheduled to speak at the UBS Warburg Global  
Healthcare Services Conference in New York City on  
Wednesday, February 6th at 3:00 p.m. Eastern Time. The  
presentation will be webcast live, with a rebroadcast  
available for a period of 30 days, and may be heard online  
at [www.labcorp.com](http://www.labcorp.com).

At the conference, Mr. Mac Mahon will reiterate Company  
guidance for 2001 and 2002, as filed in an 8-K on October  
22, 2001. Mr. Mac Mahon will state, "For 2001, we expect  
revenue growth of 13.5 percent, EBITDA margins of  
approximately 21 percent of sales and EPS growth of  
approximately 55 percent compared to 2000. For 2002, we  
expect to increase overall revenues by approximately 12

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

percent compared to 2001 and we expect EPS growth, of approximately 33 percent compared to 2001, before applying the new accounting rules regarding goodwill effective January 1, 2002. After applying the new accounting rules, we expect the non-amortization of goodwill to have an impact of approximately \$26 million in 2002, resulting in an increase to EPS of approximately \$0.36."

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2000 and subsequent SEC filings.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Registrant)

By: /s/ BRADFORD T. SMITH

-----  
Bradford T. Smith  
Executive Vice President  
and Secretary

Date: February 5, 2002